VIDEO From thenewsmarket.com and Lundbeck: Lundbeck Continues Strong Growth in Third Quarter

NEW YORK, Nov. 3, 2010 /PRNewswire/ -- See video from Lundbeck at: http://www.thenewsmarket.com/CustomLink/CustomLinks.aspx?GUID=0c5e745c-050d-4fe3-8da5-8edbb8bc6db1&bhcp=1&alertid=d0b158ec-152f-49a0-a5a9-4a7a40807750#

Danish-based H. Lundbeck A/S, a pharmaceutical company specialized in central nervous system (CNS) disorders, reports third quarter revenue of DKK 3,619 million, an increase of 7% compared to the third quarter results of 2009. Profit from operations (EBIT) was DKK 846 million, an increase of 8% compared to the same period last year. The EBIT margin for the quarter was 23.4%. Continued strong growth in key products Cipralex®, Ebixa® and Azilect®, growing 11%, 9% and 28% respectively. Available video includes Lundbeck headquarters shot and general views of laboratories.

About thenewsmarket.com

thenewsmarket.com delivers free broadcast- and streaming-quality video and multimedia content directly to media around the world, 24/7. More than 25,000 media outlets in 190+ countries use thenewsmarket.com, including the AP, BBC, CNBC, CNN, France 24, N24, nytimes.com, RAI, TVE and ZDF.  

Registered journalists can access video, audio, text, graphics and photos at http://www.thenewsmarket.com.

If you are not already registered, please take a moment to sign up - registration is quick and free: http://www.thenewsmarket.com/registration

Story Id: 20313

SOURCE thenewsmarket.com

Suggested Articles

Bluebird Bio offered the first glimpse of how its CAR-T follow-up is working in multiple myeloma patients who have tried several other treatments.

Zentalis is coming out of stealth with an $85 million series C, which will propel its lead programs into pivotal trials and broaden its pipeline.

The planned takeover centers on ARQ 531, a BTK inhibitor that triggered durable responses in patients with B-cell malignancies.